Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 7:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 1,101 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Fed Clear all
Completed Not applicable Interventional Accepts healthy volunteers

BIG Study (Brain, Immune, and Gut Health Evaluation of Infants/Young Children Fed Infant Formula, and Later Supplemental Toddler Nutrition, With 5 Specific HMOs)

NCT04957992
View directory record Official record
Conditions
Growth
Interventions
Control Infant Formula, Control Toddler Drink, Experimental Infant Formula, Experimental Toddler Drink, Human Milk, Human Milk Supplemental Formula, Human Milk Toddler Drink
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
0 Days to 14 Days
Enrollment
607 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
42
States / cities
Phoenix, Arizona • Glenwood, Arkansas • Hot Springs, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 17, 2026, 7:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

STUDY OF PF-07321332 IN HEALTHY PARTICIPANTS

NCT04756531
View directory record Official record
Conditions
Healthy Participants
Interventions
PF-07321332 Dose 1, PF-07321332 Dose 2, PF-07321332 Dose 3, PF-07321332 Dose 4, PF-07321332 Dose 5, PF-07321332 Dose 4 or Placebo (Fed)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 17, 2026, 7:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioavailability Study of MIV-711 Oral Formulations in Healthy Volunteers

NCT03443453
View directory record Official record
Conditions
Healthy
Interventions
MIV-711
Drug
Lead sponsor
Medivir
Industry
Eligibility
19 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 17, 2026, 7:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Examine the Effect of Food on the Pharmacokinetics of the Fixed Dose Combination of COREG CR and Lisinopril.

NCT00557128
View directory record Official record
Conditions
Hypertension
Interventions
COREG CR and lisinopril (FDC)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2010 · Synced Oct 17, 2026, 7:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Relative Bioavailability Study of Quinine Sulfate Capsules Under Fasting and Fed Conditions

NCT00727272
View directory record Official record
Conditions
Healthy
Interventions
Quinine Sulfate Capsules 324 mg, Quinine Sulphate Tablets 300 mg
Drug
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 20, 2010 · Synced Oct 17, 2026, 7:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Food on the Pharmacokinetics of ASTX660 in Healthy Volunteers

NCT04479800
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ASTX660
Drug
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2024 · Synced Oct 17, 2026, 7:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Growth and Tolerance of Infants Fed Milk-Based Infant Formula

NCT03967132
View directory record Official record
Conditions
Gastro-Intestinal Tolerance
Interventions
Control Infant Formula, Experimental Infant Formula, Reference Group
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
Up to 14 Days
Enrollment
189 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
19
States / cities
Tucson, Arizona • Sacramento, California • Norwich, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Oct 17, 2026, 7:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Effects of Hepatic Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate

NCT02536911
View directory record Official record
Conditions
Gaucher Disease
Interventions
eliglustat
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 79 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Miami, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 17, 2026, 7:58 AM EDT
Terminated Phase 1 Interventional

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Oral GSK4172239D Compared With Placebo in Sickle Cell Disease Participants Aged 18 to 50 Years

NCT05660265
View directory record Official record
Conditions
Hematologic Diseases, Anaemia, Sickle Cell
Interventions
GSK4172239D, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Miami, Florida • Tamarac, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 17, 2026, 7:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability and PK of NPT520-34 in Healthy Subjects

NCT03954600
View directory record Official record
Conditions
Healthy Volunteers
Interventions
NPT520-34 (125 mg), Placebos (125 mg)
Drug
Lead sponsor
Neuropore Therapies Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 17, 2026, 7:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Effect Study of AG120 in Healthy Subjects

NCT02579707
View directory record Official record
Conditions
Healthy
Interventions
AG120
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Oct 17, 2026, 7:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Effect Study of Codeine Sulfate

NCT01009892
View directory record Official record
Conditions
Pain
Interventions
Codeine Sulfate
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 17, 2026, 7:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulation of Vanzacaftor/Tezacaftor/Deutivacaftor(VNZ/TEZ/D-IVA)

NCT06299709
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VNZ/TEZ/D-IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 26, 2025 · Synced Oct 17, 2026, 7:58 AM EDT
Completed Phase 2 Interventional Results available

This Study is Done in Patients With Plaque Psoriasis and Tests How Well They Tolerate BI 730357 and How Effective it is

NCT03635099
View directory record Official record
Conditions
Psoriasis
Interventions
Placebo (fasted), BI 25 mg (fasted), BI 50 mg (fasted), BI 100 mg (fasted), BI 200 mg (fasted), Placebo (fed), BI 400 mg once daily (fed), BI 200 mg twice daily, 400 mg total (fed)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • Santa Ana, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Oct 17, 2026, 7:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Relative Bioavailability, Proton Pump Inhibitor (PPI) (Rabeprazole) Effect, Food Effect and Particle Size Effect of New Acalabrutinib Tablet in Healthy Subjects

NCT04488016
View directory record Official record
Conditions
Bioavailability, B-cell Lymphoid Cancer
Interventions
Treatment A- Part 1, Treatment B- Part 1, Treatment C - Part 1, Treatment D- Part 1, Treatment A-Part 2, Treatment B - Part 2, Treatment C - Part 2, Treatment D - Part 2
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 17, 2026, 7:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fed Study of Rabeprazole Sodium Tablets 20 mg and Aciphex® Tablets 20 mg

NCT00649493
View directory record Official record
Conditions
Healthy
Interventions
Rabeprazole Sodium Tablets 20 mg, Aciphex® Tablets 20 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
8 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 17, 2026, 7:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Canagliflozin and Metformin Immediate Release (50 mg/500 mg) FDC Tablets in Healthy Volunteers

NCT01508195
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin tablets, Metformin IR tablets, Canagliflozin/metformin IR FDC tablets
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
19 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 17, 2026, 7:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015K

NCT01387087
View directory record Official record
Conditions
Healthy Subjects, Pharmacokinetics of ASP015K
Interventions
ASP015K, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
2
States / cities
Miami, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 4, 2011 · Synced Oct 17, 2026, 7:58 AM EDT
Terminated Phase 4 Interventional Results available

Effects of Dronedarone on Cardiac Geometry and Function in Patients With Atrial Fibrillation and Left Atrial Enlargement

NCT01198873
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Dronedarone, Placebo (for Dronedarone)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
21 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
56
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 51 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2013 · Synced Oct 17, 2026, 7:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Metabolism of Danicopan in Healthy Adults

NCT04609696
View directory record Official record
Conditions
Healthy
Interventions
Danicopan: Powder-In-Capsule 1, Danicopan: Powder-In-Capsule 2, Danicopan: Tablet
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 15, 2022 · Synced Oct 17, 2026, 7:58 AM EDT
Completed Phase 2 Interventional Results available

Oral Omadacycline vs. Oral Nitrofurantoin for the Treatment of Cystitis

NCT03425396
View directory record Official record
Conditions
Uncomplicated Urinary Tract Infection, Cystitis
Interventions
Omadacycline tablets, Nitrofurantoin capsules
Drug
Lead sponsor
Paratek Pharmaceuticals Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
23
States / cities
Chula Vista, California • La Mesa, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2020 · Synced Oct 17, 2026, 7:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Phase II Growth and Safety Study of an Infant Formula for Healthy Term Infants

NCT04593147
View directory record Official record
Conditions
Infant Development
Interventions
BBN, Brand
Other
Lead sponsor
Building Block Nutritionals, LLC
Industry
Eligibility
1 Day to 14 Days
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 15, 2021 · Synced Oct 17, 2026, 7:58 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study To Investigate Safety, Tolerability, And Pharmacokinetics Of PF-00868554 In Japanese Healthy Adult Volunteers

NCT00875628
View directory record Official record
Conditions
Healthy Volunteers
Interventions
PF-00868554 or Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 22, 2009 · Synced Oct 17, 2026, 7:58 AM EDT
Completed No phase listed Observational

Tolerance of a Calorically Dense Enteral Nutrition Formula

NCT02806427
View directory record Official record
Conditions
Enteral Feeding
Interventions
Enteral Formula
Other
Lead sponsor
Société des Produits Nestlé (SPN)
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 17, 2026, 7:58 AM EDT